Tamsulosin as Adjunctive Therapy After Extracorporeal Shock Wave Lithotripsy for Renal Stones

Summary

Urolithiasis is a common health problem worldwide affecting approximately 10% of the population at some stage in their lives. The aim of this study is to evaluate the efficacy of adjuvant treatment with tamsulosin for improving the stone-free rate after a single session of extracorporeal shock wave lithotripsy (ESWL) in the treatment of radiopaque kidney stones.

Timeline

Start

2010-01-01

Primary completion

2016-08-31

Completion

2016-12-31

Outcome

Missed primary endpoint

paper 53.57% (15 of 28) for the tamsulosin group, and 48.27% (14 of 29) for the control group (p = 0.680). PMID 35685573 ↗

paper it does not increase the stone-free rate in patients with a single radiopaque renal stone of 5-20 mm in diameter. PMID 35685573 ↗

Publications

• Maldonado-Valadez RE, Valdez-Vargas AD, Alvarez JA, Rodea-Montero ER. Efficacy of Adjuvant Tamsulosin for Improving the Stone-Free Rate after Extracorporeal Shock Wave Lithotripsy in Renal Stones: A Randomized Controlled Trial. Int J Clin Pract. 2022 Jan 31;2022:3757588. doi: 10.1155/2022/3757588. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tamsulosin	Other / unclassified	0.4 mg	Oral
Background	Diclofenac	Other / unclassified	75 mg	Oral

Indications